Cayman
Showing 28201–28350 of 45550 results
-
LY2608204 is an activator of glucokinase (GK; EC50 = 42 nM).{41671} It stimulates glucose metabolism in INS-1E rat insulinoma cells (mean EC50 = 579 nM). LY2608204 (30 mg/kg) decreases plasma glucose levels in a dose-dependent manner in fasted rats.
Brand:CaymanSKU:22914 - 5 mgAvailable on backorder
LY266097 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.5 nM).{49230} It is selective for 5-HT2B over 5-HT2A and 5-HT2C receptors (Kis = 19.5 and 24.55 nM, respectively).{49231} LY266097 (100 nmol, intrathecal) reduces hind paw tactile allodynia induced by L5/L6 spinal nerve ligation in a rat model of neuropathic pain.{49232} It also reduces hyperlocomotion induced by cocaine in rats when administered at a dose of 0.63 mg/kg without reducing cocaine-induced dopamine outflow in the nucleus accumbens shell.{36202}
Brand:CaymanSKU:11935 - 1 mgAvailable on backorder
LY266097 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.5 nM).{49230} It is selective for 5-HT2B over 5-HT2A and 5-HT2C receptors (Kis = 19.5 and 24.55 nM, respectively).{49231} LY266097 (100 nmol, intrathecal) reduces hind paw tactile allodynia induced by L5/L6 spinal nerve ligation in a rat model of neuropathic pain.{49232} It also reduces hyperlocomotion induced by cocaine in rats when administered at a dose of 0.63 mg/kg without reducing cocaine-induced dopamine outflow in the nucleus accumbens shell.{36202}
Brand:CaymanSKU:11935 - 10 mgAvailable on backorder
LY266097 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.5 nM).{49230} It is selective for 5-HT2B over 5-HT2A and 5-HT2C receptors (Kis = 19.5 and 24.55 nM, respectively).{49231} LY266097 (100 nmol, intrathecal) reduces hind paw tactile allodynia induced by L5/L6 spinal nerve ligation in a rat model of neuropathic pain.{49232} It also reduces hyperlocomotion induced by cocaine in rats when administered at a dose of 0.63 mg/kg without reducing cocaine-induced dopamine outflow in the nucleus accumbens shell.{36202}
Brand:CaymanSKU:11935 - 5 mgAvailable on backorder
LY266097 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B (Ki = 0.5 nM).{49230} It is selective for 5-HT2B over 5-HT2A and 5-HT2C receptors (Kis = 19.5 and 24.55 nM, respectively).{49231} LY266097 (100 nmol, intrathecal) reduces hind paw tactile allodynia induced by L5/L6 spinal nerve ligation in a rat model of neuropathic pain.{49232} It also reduces hyperlocomotion induced by cocaine in rats when administered at a dose of 0.63 mg/kg without reducing cocaine-induced dopamine outflow in the nucleus accumbens shell.{36202}
Brand:CaymanSKU:11935 - 500 µgAvailable on backorder
LY272015 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B.{49231} It binds to 5-HT2B receptors in isolated rat fundus (Kb = 0.177 nM). LY272015 is selective for 5-HT2B receptors over 5-HT2A and 5-HT2C receptors (Kis = 3.54 and 2.1 nM, respectively), as well as α1-adrenergic receptors.{49231,52703} It reduces 5-HT-induced migration of isolated mouse aortic smooth muscle cells when used at a concentration of 100 nM.{52704} LY272015 (1 and 3 mg/kg) decreases mean arterial pressure in hypertensive DOCA-SALT rats.{52705}
Brand:CaymanSKU:31471 - 1 mgAvailable on backorder
LY272015 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT2B.{49231} It binds to 5-HT2B receptors in isolated rat fundus (Kb = 0.177 nM). LY272015 is selective for 5-HT2B receptors over 5-HT2A and 5-HT2C receptors (Kis = 3.54 and 2.1 nM, respectively), as well as α1-adrenergic receptors.{49231,52703} It reduces 5-HT-induced migration of isolated mouse aortic smooth muscle cells when used at a concentration of 100 nM.{52704} LY272015 (1 and 3 mg/kg) decreases mean arterial pressure in hypertensive DOCA-SALT rats.{52705}
Brand:CaymanSKU:31471 - 5 mgAvailable on backorder
LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}
Brand:CaymanSKU:-Out of stock
LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}
Brand:CaymanSKU:-Out of stock
LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}
Brand:CaymanSKU:-Out of stock
LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}
Brand:CaymanSKU:-Out of stock
LY2801653 is an orally bioavailable MET kinase inhibitor (Ki = 2 nM).{48025} It also inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively, in a cell-based assay). It inhibits MET autophosphorylation stimulated by hepatocyte growth factor (HGF) in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM). LY2801653 (0.01-10 µM) completely blocks cell scattering induced by HGF in DU145 cells. It reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models when administered at doses of 4 and 12 mg/kg.
Brand:CaymanSKU:25978 - 1 mgAvailable on backorder
LY2801653 is an orally bioavailable MET kinase inhibitor (Ki = 2 nM).{48025} It also inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively, in a cell-based assay). It inhibits MET autophosphorylation stimulated by hepatocyte growth factor (HGF) in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM). LY2801653 (0.01-10 µM) completely blocks cell scattering induced by HGF in DU145 cells. It reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models when administered at doses of 4 and 12 mg/kg.
Brand:CaymanSKU:25978 - 10 mgAvailable on backorder
LY2801653 is an orally bioavailable MET kinase inhibitor (Ki = 2 nM).{48025} It also inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively, in a cell-based assay). It inhibits MET autophosphorylation stimulated by hepatocyte growth factor (HGF) in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM). LY2801653 (0.01-10 µM) completely blocks cell scattering induced by HGF in DU145 cells. It reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models when administered at doses of 4 and 12 mg/kg.
Brand:CaymanSKU:25978 - 5 mgAvailable on backorder
LY2801653 is an orally bioavailable MET kinase inhibitor (Ki = 2 nM).{48025} It also inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively, in a cell-based assay). It inhibits MET autophosphorylation stimulated by hepatocyte growth factor (HGF) in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM). LY2801653 (0.01-10 µM) completely blocks cell scattering induced by HGF in DU145 cells. It reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models when administered at doses of 4 and 12 mg/kg.
Brand:CaymanSKU:25978 - 50 mgAvailable on backorder
Accumulation of the β-amyloid (Aβ) peptide in the brain is implicated as the primary cause of neurodegeneration and progression of Alzheimer’s disease.{16791} Aβ is derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase.{16790} LY2811376 is a non-peptide inhibitor of BACE1 (IC50 = 239 nM for the synthetic peptide) that demonstrates ~10-fold selectivity over BACE2 and >50-fold selectivity over the aspartyl proteases cathepsin D, pepsin, and renin.{27584} LY2811376 treatment in APP-overexpressing cells and transgenic animal models yields a dose-dependent decrease in Aβ.{27584} Furthermore, LY2811376 has been reported to reduce C99 and sAPPβ, the two primary APP cleavage products generated by BACE1.{27584}
Brand:CaymanSKU:-Out of stock
Accumulation of the β-amyloid (Aβ) peptide in the brain is implicated as the primary cause of neurodegeneration and progression of Alzheimer’s disease.{16791} Aβ is derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase.{16790} LY2811376 is a non-peptide inhibitor of BACE1 (IC50 = 239 nM for the synthetic peptide) that demonstrates ~10-fold selectivity over BACE2 and >50-fold selectivity over the aspartyl proteases cathepsin D, pepsin, and renin.{27584} LY2811376 treatment in APP-overexpressing cells and transgenic animal models yields a dose-dependent decrease in Aβ.{27584} Furthermore, LY2811376 has been reported to reduce C99 and sAPPβ, the two primary APP cleavage products generated by BACE1.{27584}
Brand:CaymanSKU:-Out of stock
Accumulation of the β-amyloid (Aβ) peptide in the brain is implicated as the primary cause of neurodegeneration and progression of Alzheimer’s disease.{16791} Aβ is derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase.{16790} LY2811376 is a non-peptide inhibitor of BACE1 (IC50 = 239 nM for the synthetic peptide) that demonstrates ~10-fold selectivity over BACE2 and >50-fold selectivity over the aspartyl proteases cathepsin D, pepsin, and renin.{27584} LY2811376 treatment in APP-overexpressing cells and transgenic animal models yields a dose-dependent decrease in Aβ.{27584} Furthermore, LY2811376 has been reported to reduce C99 and sAPPβ, the two primary APP cleavage products generated by BACE1.{27584}
Brand:CaymanSKU:-Out of stock
Accumulation of the β-amyloid (Aβ) peptide in the brain is implicated as the primary cause of neurodegeneration and progression of Alzheimer’s disease.{16791} Aβ is derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase (BACE) and γ-secretase.{16790} LY2811376 is a non-peptide inhibitor of BACE1 (IC50 = 239 nM for the synthetic peptide) that demonstrates ~10-fold selectivity over BACE2 and >50-fold selectivity over the aspartyl proteases cathepsin D, pepsin, and renin.{27584} LY2811376 treatment in APP-overexpressing cells and transgenic animal models yields a dose-dependent decrease in Aβ.{27584} Furthermore, LY2811376 has been reported to reduce C99 and sAPPβ, the two primary APP cleavage products generated by BACE1.{27584}
Brand:CaymanSKU:-Out of stock
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM).{43815} It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.{43816} It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.
Brand:CaymanSKU:26791 - 1 mgAvailable on backorder
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM).{43815} It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.{43816} It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.
Brand:CaymanSKU:26791 - 10 mgAvailable on backorder
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM).{43815} It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.{43816} It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.
Brand:CaymanSKU:26791 - 25 mgAvailable on backorder
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM).{43815} It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). It reduces differences in hind paw weight bearing between monoiodoacetic acid- and saline-injected knees in a rat model of knee joint-related chronic pain induced by monoiodoacetic acid (MIA) when administered at doses greater than or equal to 0.1 mg/kg. LY2828360 dose-dependently reduces mechanical and cold allodynia induced by paclitaxel (Item No. 10461) in mice and prevents development of morphine tolerance when administered at dose of 3 mg/kg per day for 12 days.{43816} It also reduces paclitaxel-induced allodynia in morphine-tolerant mice.
Brand:CaymanSKU:26791 - 5 mgAvailable on backorder
LY2835219 is an orally bioavailable dual inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 (IC50s = 2 and 10 nM, respectively).{29192} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29193}
Brand:CaymanSKU:21560 -Out of stock
LY2835219 is an orally bioavailable dual inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 (IC50s = 2 and 10 nM, respectively).{29192} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29193}
Brand:CaymanSKU:21560 -Out of stock
LY2835219 is an orally bioavailable dual inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 (IC50s = 2 and 10 nM, respectively).{29192} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29193}
Brand:CaymanSKU:21560 -Out of stock
LY2835219 is an orally bioavailable dual inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 (IC50s = 2 and 10 nM, respectively).{29192} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29193}
Brand:CaymanSKU:21560 -Out of stock
LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively).{28691,29192,29193} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29192,29193}
Brand:CaymanSKU:-Available on backorder
LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively).{28691,29192,29193} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29192,29193}
Brand:CaymanSKU:-Available on backorder
LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively).{28691,29192,29193} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29192,29193}
Brand:CaymanSKU:-Available on backorder
LY2874455 is a pan-inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases with IC50 values of 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively.{33523} It has been shown to inhibit proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice.{33523}
Brand:CaymanSKU:20843 -Out of stock
LY2874455 is a pan-inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases with IC50 values of 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively.{33523} It has been shown to inhibit proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice.{33523}
Brand:CaymanSKU:20843 -Out of stock
LY2874455 is a pan-inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases with IC50 values of 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively.{33523} It has been shown to inhibit proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice.{33523}
Brand:CaymanSKU:20843 -Out of stock
LY2874455 is a pan-inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases with IC50 values of 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively.{33523} It has been shown to inhibit proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice.{33523}
Brand:CaymanSKU:20843 -Out of stock
LY2886721 selectively inhibits the β-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1).{33660} BACE performs the first cleavage step in the Aβ cascade; thus, its inhibition by LY2886721 decreases production of all forms of the Aβ peptide.{33661} A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer’s disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.
Brand:CaymanSKU:21599 -Out of stock
LY2886721 selectively inhibits the β-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1).{33660} BACE performs the first cleavage step in the Aβ cascade; thus, its inhibition by LY2886721 decreases production of all forms of the Aβ peptide.{33661} A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer’s disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.
Brand:CaymanSKU:21599 -Out of stock
LY2886721 selectively inhibits the β-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1).{33660} BACE performs the first cleavage step in the Aβ cascade; thus, its inhibition by LY2886721 decreases production of all forms of the Aβ peptide.{33661} A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer’s disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.
Brand:CaymanSKU:21599 -Out of stock
LY2886721 selectively inhibits the β-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1).{33660} BACE performs the first cleavage step in the Aβ cascade; thus, its inhibition by LY2886721 decreases production of all forms of the Aβ peptide.{33661} A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer’s disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.
Brand:CaymanSKU:21599 -Out of stock
Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM.{14782} LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.{16702}
Brand:CaymanSKU:10009768 - 1 mgAvailable on backorder
Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM.{14782} LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.{16702}
Brand:CaymanSKU:10009768 - 10 mgAvailable on backorder
Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM.{14782} LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.{16702}
Brand:CaymanSKU:10009768 - 5 mgAvailable on backorder
Leukotriene B4 (LTB4) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. LY293111 is a potent antagonist of the leukotriene B4 (LTB4) receptor, BLT1, that inhibits the specific binding of radiolabeled-LTB4 to isolated human neutrophils with an IC50 value of 17.6 nM and inhibits the LTB4-induced chemotaxis of human neutrophils with an IC50 value of 6.3 nM.{14782} LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 human pancreatic cancer cells in vitro (250-1,000 nM) and subcutaneous xenografts in athymic mice (250 mg/kg/day), inducing apoptosis and S-phase arrest.{16702}
Brand:CaymanSKU:10009768 - 500 µgAvailable on backorder
LY294002 is a selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a 2.7-fold greater potency than quercetin. LY294002 inhibits purified PI3K with an IC50 of 1.4 µM.{6296}
Brand:CaymanSKU:70920 - 10 mgAvailable on backorder
LY294002 is a selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a 2.7-fold greater potency than quercetin. LY294002 inhibits purified PI3K with an IC50 of 1.4 µM.{6296}
Brand:CaymanSKU:70920 - 25 mgAvailable on backorder
LY294002 is a selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a 2.7-fold greater potency than quercetin. LY294002 inhibits purified PI3K with an IC50 of 1.4 µM.{6296}
Brand:CaymanSKU:70920 - 5 mgAvailable on backorder
LY294002 is a selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a 2.7-fold greater potency than quercetin. LY294002 inhibits purified PI3K with an IC50 of 1.4 µM.{6296}
Brand:CaymanSKU:70920 - 50 mgAvailable on backorder
Smoothened (Smo) is a GPCR-like receptor that, with Patched, mediates hedgehog (Hh) signaling to regulate gene expression through the Gli transcription factors.{21774} LY2940680 is an antitumor agent that binds to the human Smo receptor and inhibits Sonic Hh-induced Gli1 expression (IC50 = ~2.4 nM in vitro).{27679,27681,27680} The potential anticancer activity of LY2940680 is currently under clinical investigation.
Brand:CaymanSKU:- Smoothened (Smo) is a GPCR-like receptor that, with Patched, mediates hedgehog (Hh) signaling to regulate gene expression through the Gli transcription factors.{21774} LY2940680 is an antitumor agent that binds to the human Smo receptor and inhibits Sonic Hh-induced Gli1 expression (IC50 = ~2.4 nM in vitro).{27679,27681,27680} The potential anticancer activity of LY2940680 is currently under clinical investigation.
Brand:CaymanSKU:- Smoothened (Smo) is a GPCR-like receptor that, with Patched, mediates hedgehog (Hh) signaling to regulate gene expression through the Gli transcription factors.{21774} LY2940680 is an antitumor agent that binds to the human Smo receptor and inhibits Sonic Hh-induced Gli1 expression (IC50 = ~2.4 nM in vitro).{27679,27681,27680} The potential anticancer activity of LY2940680 is currently under clinical investigation.
Brand:CaymanSKU:-
LY2955303 is a potent antagonist of retinoic acid receptor γ (RARγ; Ki = 1.1 nM).{42717} It is selective for RARγ over RARα and RARβ (Kis = >1,700 and >2,980 nM, respectively). LY2955303 reduces differential weight bearing between the contralateral and ipsilateral limbs in a rat model of monoiodoacetate-induced osteoarthritis (ED50 = 0.72 mg/kg).
Brand:CaymanSKU:25833 - 1 mgAvailable on backorder
LY2955303 is a potent antagonist of retinoic acid receptor γ (RARγ; Ki = 1.1 nM).{42717} It is selective for RARγ over RARα and RARβ (Kis = >1,700 and >2,980 nM, respectively). LY2955303 reduces differential weight bearing between the contralateral and ipsilateral limbs in a rat model of monoiodoacetate-induced osteoarthritis (ED50 = 0.72 mg/kg).
Brand:CaymanSKU:25833 - 10 mgAvailable on backorder
LY2955303 is a potent antagonist of retinoic acid receptor γ (RARγ; Ki = 1.1 nM).{42717} It is selective for RARγ over RARα and RARβ (Kis = >1,700 and >2,980 nM, respectively). LY2955303 reduces differential weight bearing between the contralateral and ipsilateral limbs in a rat model of monoiodoacetate-induced osteoarthritis (ED50 = 0.72 mg/kg).
Brand:CaymanSKU:25833 - 25 mgAvailable on backorder
LY2955303 is a potent antagonist of retinoic acid receptor γ (RARγ; Ki = 1.1 nM).{42717} It is selective for RARγ over RARα and RARβ (Kis = >1,700 and >2,980 nM, respectively). LY2955303 reduces differential weight bearing between the contralateral and ipsilateral limbs in a rat model of monoiodoacetate-induced osteoarthritis (ED50 = 0.72 mg/kg).
Brand:CaymanSKU:25833 - 5 mgAvailable on backorder
LY3000328 is a potent cathepsin S inhibitor (IC50 = 7.7 nM for the human enzyme).{53427} It is selective for cathepsin S over cathepsin L, K, B, and V (IC50s = >10,000, >10,000, 4,390, and 21,500 nM, respectively). LY3000328 (1-30 mg/kg) reduces aortic diameter in a mouse model of calcium chloride-induced abdominal aortic aneurysm.
Brand:CaymanSKU:29729 - 1 mgAvailable on backorder
LY3000328 is a potent cathepsin S inhibitor (IC50 = 7.7 nM for the human enzyme).{53427} It is selective for cathepsin S over cathepsin L, K, B, and V (IC50s = >10,000, >10,000, 4,390, and 21,500 nM, respectively). LY3000328 (1-30 mg/kg) reduces aortic diameter in a mouse model of calcium chloride-induced abdominal aortic aneurysm.
Brand:CaymanSKU:29729 - 10 mgAvailable on backorder
LY3000328 is a potent cathepsin S inhibitor (IC50 = 7.7 nM for the human enzyme).{53427} It is selective for cathepsin S over cathepsin L, K, B, and V (IC50s = >10,000, >10,000, 4,390, and 21,500 nM, respectively). LY3000328 (1-30 mg/kg) reduces aortic diameter in a mouse model of calcium chloride-induced abdominal aortic aneurysm.
Brand:CaymanSKU:29729 - 5 mgAvailable on backorder
LY3000328 is a potent cathepsin S inhibitor (IC50 = 7.7 nM for the human enzyme).{53427} It is selective for cathepsin S over cathepsin L, K, B, and V (IC50s = >10,000, >10,000, 4,390, and 21,500 nM, respectively). LY3000328 (1-30 mg/kg) reduces aortic diameter in a mouse model of calcium chloride-induced abdominal aortic aneurysm.
Brand:CaymanSKU:29729 - 500 µgAvailable on backorder
LY3009120 is an inhibitor of Raf kinases, including A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates).{33835,33836} It also inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays).{33836} LY3009120 induces Raf dimerization and, unlike vemurafenib (PLX4032; Item No. 10618) and dabrafenib (Item No. 16989), inhibits kinase activity of induced dimers.{33836} It inhibits cell cycling in B-Raf or Ras mutant cancer cells and has significant antitumor activity in B-Raf and K-Ras mutant preclinical models of colorectal cancer.{33836,33837} LY3009120 is also active against B-Raf in-frame deletions in vitro and in mouse models.{33834}
Brand:CaymanSKU:21504 -Out of stock
LY3009120 is an inhibitor of Raf kinases, including A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates).{33835,33836} It also inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays).{33836} LY3009120 induces Raf dimerization and, unlike vemurafenib (PLX4032; Item No. 10618) and dabrafenib (Item No. 16989), inhibits kinase activity of induced dimers.{33836} It inhibits cell cycling in B-Raf or Ras mutant cancer cells and has significant antitumor activity in B-Raf and K-Ras mutant preclinical models of colorectal cancer.{33836,33837} LY3009120 is also active against B-Raf in-frame deletions in vitro and in mouse models.{33834}
Brand:CaymanSKU:21504 -Out of stock
LY3009120 is an inhibitor of Raf kinases, including A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates).{33835,33836} It also inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays).{33836} LY3009120 induces Raf dimerization and, unlike vemurafenib (PLX4032; Item No. 10618) and dabrafenib (Item No. 16989), inhibits kinase activity of induced dimers.{33836} It inhibits cell cycling in B-Raf or Ras mutant cancer cells and has significant antitumor activity in B-Raf and K-Ras mutant preclinical models of colorectal cancer.{33836,33837} LY3009120 is also active against B-Raf in-frame deletions in vitro and in mouse models.{33834}
Brand:CaymanSKU:21504 -Out of stock
LY3009120 is an inhibitor of Raf kinases, including A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates).{33835,33836} It also inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays).{33836} LY3009120 induces Raf dimerization and, unlike vemurafenib (PLX4032; Item No. 10618) and dabrafenib (Item No. 16989), inhibits kinase activity of induced dimers.{33836} It inhibits cell cycling in B-Raf or Ras mutant cancer cells and has significant antitumor activity in B-Raf and K-Ras mutant preclinical models of colorectal cancer.{33836,33837} LY3009120 is also active against B-Raf in-frame deletions in vitro and in mouse models.{33834}
Brand:CaymanSKU:21504 -Out of stock
LY303511 is a close structural analog of LY294002 (Item No. 70920), a selective phosphatidylinositol 3-kinase (PI3K) inhibitor.{32629} LY303511, however, does not inhibit PI3K-dependent phosphorylation of Akt but instead has been shown to inhibit mTOR-dependent phosphorylation of S6K.{32629} It can reduce cell proliferation in human lung epithelial adenocarcinoma cells, blocking G2/M progression and inhibiting casein kinase 2 activity.{32629} LY303511 demonstrates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing activity in HeLa cells that are refractory to TRAIL-induced apoptosis.{32630} LY303511 is also reported to block voltage-gated potassium (Kv) channels.{32631}
Brand:CaymanSKU:- LY303511 is a close structural analog of LY294002 (Item No. 70920), a selective phosphatidylinositol 3-kinase (PI3K) inhibitor.{32629} LY303511, however, does not inhibit PI3K-dependent phosphorylation of Akt but instead has been shown to inhibit mTOR-dependent phosphorylation of S6K.{32629} It can reduce cell proliferation in human lung epithelial adenocarcinoma cells, blocking G2/M progression and inhibiting casein kinase 2 activity.{32629} LY303511 demonstrates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizing activity in HeLa cells that are refractory to TRAIL-induced apoptosis.{32630} LY303511 is also reported to block voltage-gated potassium (Kv) channels.{32631}
Brand:CaymanSKU:-
LY310762 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 249 nM for guinea pig receptors).{40403} It is selective for 5-HT1D over the 5-HT1B receptor, where it inhibits binding of radiolabeled citalopram by only 32% when used at a concentration of 1,000 nM. LY310762 potentiates 5-HT (Item No. 14332) release stimulated by potassium in guinea pig cortex (EC50 = 31 nM). It also reverses vasodilation induced by 5-HT in rat kidney perfused by phenylephrine (Item Nos. 17205 | 18619) when administered at a dose of 1 mg/kg.{40402}
Brand:CaymanSKU:22938 - 10 mgAvailable on backorder
LY310762 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 249 nM for guinea pig receptors).{40403} It is selective for 5-HT1D over the 5-HT1B receptor, where it inhibits binding of radiolabeled citalopram by only 32% when used at a concentration of 1,000 nM. LY310762 potentiates 5-HT (Item No. 14332) release stimulated by potassium in guinea pig cortex (EC50 = 31 nM). It also reverses vasodilation induced by 5-HT in rat kidney perfused by phenylephrine (Item Nos. 17205 | 18619) when administered at a dose of 1 mg/kg.{40402}
Brand:CaymanSKU:22938 - 25 mgAvailable on backorder
LY310762 is an antagonist of the serotonin (5-HT) receptor subtype 5-HT1D (Ki = 249 nM for guinea pig receptors).{40403} It is selective for 5-HT1D over the 5-HT1B receptor, where it inhibits binding of radiolabeled citalopram by only 32% when used at a concentration of 1,000 nM. LY310762 potentiates 5-HT (Item No. 14332) release stimulated by potassium in guinea pig cortex (EC50 = 31 nM). It also reverses vasodilation induced by 5-HT in rat kidney perfused by phenylephrine (Item Nos. 17205 | 18619) when administered at a dose of 1 mg/kg.{40402}
Brand:CaymanSKU:22938 - 5 mgAvailable on backorder
Secreted phospholipase A2 (sPLA2) isoforms are low molecular weight, millimolar calcium-dependent enzymes that hydrolyze the fatty acid from the sn-2 position of membrane phospholipids.{18627} Group IIA sPLA2, also known as sPLA2IIA and non-pancreatic sPLA2, has roles in the regulation of eicosanoid synthesis and may modulate inflammatory signaling.{18627,10619} LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 µM) that interacts with the active site of the enzyme in a non-covalent manner.{10619,29121} It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2).{29121} LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.{4458,7824,9354,8035}
Brand:CaymanSKU:-Available on backorder
Secreted phospholipase A2 (sPLA2) isoforms are low molecular weight, millimolar calcium-dependent enzymes that hydrolyze the fatty acid from the sn-2 position of membrane phospholipids.{18627} Group IIA sPLA2, also known as sPLA2IIA and non-pancreatic sPLA2, has roles in the regulation of eicosanoid synthesis and may modulate inflammatory signaling.{18627,10619} LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 µM) that interacts with the active site of the enzyme in a non-covalent manner.{10619,29121} It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2).{29121} LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.{4458,7824,9354,8035}
Brand:CaymanSKU:-Available on backorder
Secreted phospholipase A2 (sPLA2) isoforms are low molecular weight, millimolar calcium-dependent enzymes that hydrolyze the fatty acid from the sn-2 position of membrane phospholipids.{18627} Group IIA sPLA2, also known as sPLA2IIA and non-pancreatic sPLA2, has roles in the regulation of eicosanoid synthesis and may modulate inflammatory signaling.{18627,10619} LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 µM) that interacts with the active site of the enzyme in a non-covalent manner.{10619,29121} It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2).{29121} LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.{4458,7824,9354,8035}
Brand:CaymanSKU:-Available on backorder
LY315920 is an inhibitor of human group IIA (hGIIA) secretory phospholipase A2 (sPLA2; IC50 = 9 nM).{3601} It also potently inhibits human GIIE and GX isoforms, as well as the corresponding mouse isoforms, but poorly inhibits other PLA2 enzymes.{3601,30706,30705,12332} LY315920 inhibits sPLA2-induced release of thromboxane A2 from isolated guinea pig lung bronchoalveolar lavage cells (IC50 = 0.79 µM).{30706} Intravenous or oral administration of LY315920 to transgenic mice expressing human sPLA2 inhibits serum sPLA2 activity in a dose-related manner over four hours.{30706}
Brand:CaymanSKU:-Available on backorder
LY315920 is an inhibitor of human group IIA (hGIIA) secretory phospholipase A2 (sPLA2; IC50 = 9 nM).{3601} It also potently inhibits human GIIE and GX isoforms, as well as the corresponding mouse isoforms, but poorly inhibits other PLA2 enzymes.{3601,30706,30705,12332} LY315920 inhibits sPLA2-induced release of thromboxane A2 from isolated guinea pig lung bronchoalveolar lavage cells (IC50 = 0.79 µM).{30706} Intravenous or oral administration of LY315920 to transgenic mice expressing human sPLA2 inhibits serum sPLA2 activity in a dose-related manner over four hours.{30706}
Brand:CaymanSKU:-Available on backorder
LY315920 is an inhibitor of human group IIA (hGIIA) secretory phospholipase A2 (sPLA2; IC50 = 9 nM).{3601} It also potently inhibits human GIIE and GX isoforms, as well as the corresponding mouse isoforms, but poorly inhibits other PLA2 enzymes.{3601,30706,30705,12332} LY315920 inhibits sPLA2-induced release of thromboxane A2 from isolated guinea pig lung bronchoalveolar lavage cells (IC50 = 0.79 µM).{30706} Intravenous or oral administration of LY315920 to transgenic mice expressing human sPLA2 inhibits serum sPLA2 activity in a dose-related manner over four hours.{30706}
Brand:CaymanSKU:-Available on backorder
LY315920 is an inhibitor of human group IIA (hGIIA) secretory phospholipase A2 (sPLA2; IC50 = 9 nM).{3601} It also potently inhibits human GIIE and GX isoforms, as well as the corresponding mouse isoforms, but poorly inhibits other PLA2 enzymes.{3601,30706,30705,12332} LY315920 inhibits sPLA2-induced release of thromboxane A2 from isolated guinea pig lung bronchoalveolar lavage cells (IC50 = 0.79 µM).{30706} Intravenous or oral administration of LY315920 to transgenic mice expressing human sPLA2 inhibits serum sPLA2 activity in a dose-related manner over four hours.{30706}
Brand:CaymanSKU:-Available on backorder
LY3177833 is an orally bioavailable inhibitor of Cdc7 kinase (IC50 = 3.3 nM for ADP production in an enzyme assay).{48053} It inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM). LY3177833 reduces tumor growth in an SW620 human colorectal adenocarcinoma mouse xenograft model when administered at doses of 10, 20, and 30 mg/kg twice per day.
Brand:CaymanSKU:25988 - 10 mgAvailable on backorder
LY3177833 is an orally bioavailable inhibitor of Cdc7 kinase (IC50 = 3.3 nM for ADP production in an enzyme assay).{48053} It inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM). LY3177833 reduces tumor growth in an SW620 human colorectal adenocarcinoma mouse xenograft model when administered at doses of 10, 20, and 30 mg/kg twice per day.
Brand:CaymanSKU:25988 - 25 mgAvailable on backorder
LY3177833 is an orally bioavailable inhibitor of Cdc7 kinase (IC50 = 3.3 nM for ADP production in an enzyme assay).{48053} It inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM). LY3177833 reduces tumor growth in an SW620 human colorectal adenocarcinoma mouse xenograft model when administered at doses of 10, 20, and 30 mg/kg twice per day.
Brand:CaymanSKU:25988 - 5 mgAvailable on backorder
LY3177833 is an orally bioavailable inhibitor of Cdc7 kinase (IC50 = 3.3 nM for ADP production in an enzyme assay).{48053} It inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM). LY3177833 reduces tumor growth in an SW620 human colorectal adenocarcinoma mouse xenograft model when administered at doses of 10, 20, and 30 mg/kg twice per day.
Brand:CaymanSKU:25988 - 50 mgAvailable on backorder
LY3200882 is an ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI).{43234} It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.
Brand:CaymanSKU:25276 - 1 mgAvailable on backorder
LY3200882 is an ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI).{43234} It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.
Brand:CaymanSKU:25276 - 10 mgAvailable on backorder
LY3200882 is an ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI).{43234} It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.
Brand:CaymanSKU:25276 - 25 mgAvailable on backorder
LY3200882 is an ATP-competitive inhibitor of TGF-β receptor type 1 (TGF-βRI).{43234} It inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo and exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model.
Brand:CaymanSKU:25276 - 5 mgAvailable on backorder